SVB Securities analyst David Risinger maintained a Buy rating on Theravance Biopharma (TBPH – Research Report) on July 15 and set a price target of $12.00. The company's shares closed last Friday at $8.77. According to TipRanks.com, Risinger is a 2-star analyst with an average return of 2.1% and a 53.8% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Johnson & Johnson. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theravance Biopharma with a $11.17 average price target, implying a 32.7% upside from current levels. In a report issued on July 14, H.C.
https://www.tipranks.com/news/blurbs/theravance-biopharma-tbph-gets-a-buy-rating-from-svb-securities?utm_source=advfn.com&utm_medium=referral
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Theravance Biopharma Charts.
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Theravance Biopharma Charts.